No 04 2025

Johnny Mogensen most recently comes from a position as Denmark’s research and innovation attaché in Boston, USA. He has held several positions in the Danish Agency for Higher Education and Science and has also previously been posted to Brussels as an adviser to Denmark’s EU delegation and as a national expert to the European Commission.

Lionel Leck's research focuses on paediatric cancer, particularly neuroblastoma – one of the most commonly diagnosed childhood cancers with a poor prognosis.

Hansa Biopharma has announced that Fredrik Röök has been appointed as VP Business Development effective August 17.

The two companies have entered into a strategic partnership featuring customized development services for Xdarzane, Xbrane's biosimilar candidate referencing Darzalex (daratumumab).

Camurus has received a Complete Response Letter from the US Food and Drug Administration regarding its New Drug Application for CAM2029 (Oclaiz), a once-monthly octreotide treatment for patients with acromegaly.

Evaxion announces new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML). Developed with AI-Immunology, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigens from the dark genome.

The company has appointed Ida Nordberg as its new Chief Financial Officer as the company prepares for the next phase of commercialization and international expansion.